Immunohistochemical localization of somatostatin receptor sst2A in sarcoid granulomas.
Immunohistochemical localization of somatostatin receptor sst2A in sarcoid granulomas.
复制标题
肉芽肿中生长抑素受体 sst2A 的免疫组织化学定位。
DOI：
10.1046/j.1365-2362.1999.00498.x
复制
发表时间：
1999
影响因子：
5.5
通讯作者：
vanHagen,PM
中科院分区：
文献类型：
--
作者：
tenBokum,AM;Hofland,LJ;deJong,G;Bouma,J;Melief,MJ;Kwekkeboom,DJ;Schonbrunn,A;Mooy,CM;Laman,JD;Lamberts,SW;vanHagen,PM
背景在之前的一项研究中，我们通过体内生长抑素受体闪烁扫描和体外放射自显影证明了患有结节病和其他肉芽肿性疾病的患者的炎症病变中存在生长抑素受体（一种具有免疫调节特性的神经肽）。然而，不可能准确识别哪些细胞类型表达生长抑素受体以及表达哪种亚型。在这项研究中，我们使用了针对 sst2A 受体的多克隆抗血清，以更准确地识别结节病和其他肉芽肿性疾病中表达 sst2A 的细胞。设计使用 sst2A 特异性抗血清，通过免疫组织化学方法对 12 名结节病患者、一名巨细胞动脉炎患者和一名韦格纳肉芽肿病患者的组织活检进行了研究。两名结节病患者接受了生长抑素类似物奥曲肽（100 μg t.i.d.）治疗。结果 12 例结节病活检中的 9 例以及两例非结节肉芽肿活检中上皮样细胞、多核巨细胞和 CD68+巨噬细胞亚群的 sst2A 染色呈阳性。奥曲肽治疗使二分之一的治疗患者的临床症状得到改善。结论肉芽肿巨噬细胞、上皮样细胞和巨细胞上生长抑素受体的鉴定，以及生长抑素类似物成功治疗一名结节病患者，可能为肉芽肿性疾病的治疗提供新的可能性。
BackgroundIn a previous study, we demonstrated the presence of receptors for somatostatin, a neuropeptide with immunoregulatory properties, in the inflammatory lesions of patients suffering from sarcoidosis and other granulomatous diseases byin vivosomatostatin receptor scintigraphy andin vitroautoradiography. However, it was not possible to identify exactly which cell types expressed the somatostatin receptors and which subtype was expressed. In this study we used a polyclonal antiserum directed against the sst2Areceptor to identify more accurately the sst2A‐expressing cells in sarcoidosis and other granulomatous diseases.DesignTissue biopsies from 12 patients with sarcoidosis, one patient with giant cell arteritis and one patient with Wegener's granulomatosis were studied by immunohistochemistry with the sst2A‐specific antiserum. Two of the sarcoidosis patients were treated with the somatostatin analogue octreotide (100 μg t.i.d.).ResultsEpithelioid cells, multinucleated giant cells and a subset of CD68+macrophages stained positive for sst2Ain 9 out of 12 of the sarcoid biopsies and in both non‐sarcoid granuloma biopsies. Treatment with octreotide resulted in clinical improvement in one out of two treated patients.ConclusionThe identification of somatostatin receptors on granuloma macrophages, epithelioid cells and giant cells, and the successful treatment of one patient with sarcoidosis with a somatostatin analogue, may offer new possibilities for treatment of granulomatous diseases.